Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?

Roxane Claverie Marine Perriguey Audrey Rico Clemence Boutiere Sarah Demortiere Pierre Durozard Frederic Hilezian Clea Dubrou Frederic VelyJean PelletierBertrand Audoin Sandra Vukusic

Published in: Neurology(R) neuroimmunology & neuroinflammation (2023)

The efficacy of RTX outlasted substantial reconstitution of circulating B cells in PwMS, which suggests that renewal of the immune system underlies the prolonged effect of RTX in MS. These findings suggest that extended interval dosing of RTX that leads to a significant reconstitution of circulating B cells is safe in PwMS, could reduce the risk of infection, and could improve vaccine efficacy.

Keyphrases

multiple sclerosis
mass spectrometry
ms ms